An interventional study of Percuteneous Coronary Intervention and Optimal Medical Therapy in Ischemic Heart Disease and Chronic Total Occlusion of Coronary Artery, sponsored by Aarhus University Hospital Skejby. Recruiting at 27 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Myocardial Ischemia with a site in Spain — 14 open to participants now, 26 under way, 1 of them phase 3. Myocardial Ischemia · Spain.
Among the 76 studies in Myocardial Ischemia with a site in Spain, this one is the 7th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2018, is one of 22 with no phase, reaches primary completion later than 22 of the 25 other live ones, and was the 28th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →14 of the 76 studies in Myocardial Ischemia with a site in Spain are open now. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Spain, United States, Belgium and 1 more country
Ages 18–85
Instituto de Investigación Biomédica de Salamanca · Sites in Spain, France, Netherlands
Ages 18+
Fundación EPIC · Sites in Spain
Ages 18+
University of Cadiz · Sites in Spain
Ages 18–80
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,560 is above the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 324 across the 39 interventional studies, 501 across the 37 observational. Of the 39 that completed or were terminated, 8 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 76 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital Skejby is the lead sponsor of 60 studies on the registry; 3 are open to participants now.
Aarhus University Hospital Skejby has 9 studies filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Myocardial Ischemia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT05788432Fundación EPICSequent Extended Study | 2026-12-01 |
| NCT05617599Fundación EPICSUPRAFLEX CRUZ PMCF Study ( rEpic05 ) | 2026-12-01 |
| NCT06621524OrbusNeichEucaLimus Post-Market Registry | 2027-01 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 76 studies in Myocardial Ischemia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study design
Prospective randomized open labeled multicenter study
Hypotheses
Inclusion Criteria
Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:
Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL > 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO
Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO
Cohort C: patients enrolled but not randomized in cohort A or B
Exclusion criteria (for both cohort A and B)
Primary endpoint
Cohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial infarction, clinically driven revascularization*), hospitalization for heart failure or incidence of malignant arrhythmias.
*CCS class ≥ 2 and/or QoL score \< 60. Same criteria used as for allocation to Cohort B
Cohort B: SAQ Quality of Life Assessment after 6 months.
Number of patients
1,560 (1200 in cohort A/360 in cohort B
Follow up time
Cohort A: 5 years Cohort B: 6 months
A chronic total occlusion (CTO) is observed in up to (1) 30 % of patients undergoing diagnostic coronary angiography. The presence of a CTO is associated with worse outcome compared to non-occlusive coronary artery disease.
Percutaneous Coronary Intervention (PCI) treatment of CTO lesions has gained much attention over the last decade due to introduction of new techniques and devices resulting in high success rates in dedicated centers. However the scientific evidence is mainly based on observational studies and expert consensus. The current European and American guidelines on revascularization does not provide any clear recommendations how to manage patients with CTO.
The indication of treating a CTO lesion, or any other lesion with PCI for that matter, is either to relieve symptoms or improve prognosis. However, to date, there are no randomized clinical trials showing any prognostic benefit from CTO revascularization. Data from randomized clinical trials are also scarce regarding improvement of symptoms and Quality of life (QoL). In the recently presented DECISION-CTO study, patients were randomized to PCI vs. OMT, and the study failed to demonstrate a prognostic or symptomatic benefit of PCI vs. OMT. However, the study was prematurely terminated due to slow inclusion rate and had a high crossover rate and a high proportion did not have a quality of life score at follow-up. The fact that both the Decision CTO and the Euro CTO trial failed to include the pre-specified number of patients, makes it difficult to draw any conclusions on how to treat these patients. The preliminary results from both trials indicate that CTO PCI seems to be a safe procedure and might improve symptoms and QoL. In the randomized EXPLORE trial, patients with ST-elevation myocardial infarction (STEMI)and a concomitant CTO in a non infarct related artery was investigated. This study showed no benefit in terms of improving left ventricular function due to CTO-PCI of the concomitant CTO, although the procedure was safe.
Meta-analysis of observational studies comparing the prognosis after successful vs. unsuccessful CTO PCI indicate prognostic and symptomatic benefit of successful CTO PCI. However, these studies often lack data regarding ischemia burden and viability. The fact that the non-successful PCI patients consistently in these studies have higher risk profile, indicating the presence of residual confounders not accounted for in the multivariate statistical models, makes the interpretation of these data in a clinical setting difficult. The non-randomized FACTOR trial demonstrated a positive outcome for quality of life, but only in symptomatic patients. Data from the OPEN-CTO registry demonstrated an improvement of the Seattle Angina Questionnaire for quality of life by 10.8 points after a successful CTO-procedure. In addition to symptomatic improvement, a successful CTO procedure can reduce the amount of myocardium susceptible to ischemia in patients with at least mild to moderate ischemia at baseline and by that the prognosis can be improved (mortality, myocardial infarction, ventricular arrhythmias).
Hence, the interventional management of CTO lesions must address whether it is indicated on symptomatic and/or prognostic basis. These questions have not been sufficiently addressed in the previous trials and we need evidence from randomized clinical trials on how to treat these patients. We therefore designed this randomized clinical trial addressing the impact of CTO PCI on outcome. Patients are included in 2 different patient cohorts depending on level of symptoms and level of myocardial ischemia. From previous studies, we know that it is most probably only patients with at least moderate myocardial ischemia who will benefit from CTO PCI in terms of improving MACCE, and only symptomatic patients who will benefit with regard to improvement of quality of life following CTO PCI.
Before entering the study all patients will be subject to a 3-month period with titration of optimal medical therapy. Hereafter the patients will be eligible for inclusion in one of two cohorts based on level of ischemia and presence of symptoms:
Cohort A: Comprise CTO patients who are asymptomatic (CCS class \<2 and SAQ QoL> 60) but have moderate myocardial ischemia (>10% of the left ventricle) on MR or rubidium-PET. These patients will be randomized to CTO PCI or OMT and followed up to 10 years.
Cohort B: Comprise symptomatic CTO patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60) with at least 5% reversible ischemia. These patients will be randomized to CTO PCI or OMT. The patients randomized to OMT will be offered CTO PCI procedure 6 months after randomization following assessment of Seattle Angina Questionnaire quality of life score.
Cohort C - Patients enrolled but not eligible for randomization All patients enrolled at baseline but who do not meet the criteria described in cohort A and B for randomization. Registry based follow-up (optional) is performed at the same time points as in Cohort A.
This is the first randomized study that addresses improvement of prognosis and quality of life following PCI of CTO lesions specifically.
The purpose of this study is twofold:
Hypotheses
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:
Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL > 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO
Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO assess by nuclear imaging.
Cohort C: Screening population not eligible for randomization in cohort A or B
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Percuteneous Coronary Intervention
Other: Optimal Medical Therapy
PCI of Chronic Total Occlusions
Initiation and titration of optimal medical therapy in the control arm.
Major Adverse Cerebral and Cardiovascular Events
Primary outcome in the Cohort A.
Time frame: 5 Year
Quality of life - Seattle Angina Questionnaire
Primary outome in the Cohort B
Time frame: 6 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Undecided
Started Nov 2018 (actual). Primary completion is estimated for Nov 2028, 119 months after the start.
Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 119 months is above that.
Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital Skejby